Kura Oncology (NASDAQ:KURA) Announces Earnings Results

Kura Oncology (NASDAQ:KURA) announced its quarterly earnings results on Thursday. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.03), Briefing.com reports. During the same quarter in the prior year, the business earned ($0.50) earnings per share. The firm’s revenue was up .0% compared to the same quarter last year.

Kura Oncology Price Performance

Shares of KURA traded up $0.04 during trading hours on Friday, hitting $20.63. 605,625 shares of the stock were exchanged, compared to its average volume of 1,285,810. The company has a debt-to-equity ratio of 0.02, a quick ratio of 12.26 and a current ratio of 12.26. Kura Oncology has a 12-month low of $7.41 and a 12-month high of $24.17. The company has a market cap of $1.57 billion, a price-to-earnings ratio of -9.92 and a beta of 0.89. The stock’s 50-day moving average price is $20.65 and its two-hundred day moving average price is $15.85.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on KURA. HC Wainwright reissued a “buy” rating and issued a $32.00 price target on shares of Kura Oncology in a report on Friday. Wedbush reaffirmed an “outperform” rating and set a $37.00 target price on shares of Kura Oncology in a research note on Friday. StockNews.com downgraded Kura Oncology from a “hold” rating to a “sell” rating in a research note on Monday, April 15th. Finally, JMP Securities upped their target price on Kura Oncology from $22.00 to $32.00 and gave the stock a “market outperform” rating in a research note on Wednesday, January 31st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Kura Oncology presently has an average rating of “Moderate Buy” and an average price target of $28.28.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.